Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis
Identifieur interne : 002497 ( Main/Exploration ); précédent : 002496; suivant : 002498Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis
Auteurs : Michael H. Schiff [États-Unis] ; Andrew Whelton [États-Unis]Source :
- Seminars in Arthritis and Rheumatism [ 0049-0172 ] ; 2000.
English descriptors
- KwdEn :
- Teeft :
- Abnormality, Adverse events, Adverse reactions, Antimalarial, Antirheumatic drugs, Arthritis, Arthritis rheum, Autoimmune diseases, Azathioprine, Biopsy, Consensus guidelines, Creatinine, Creatinine clearance, Cyclosporin, Cyclosporine, Dmard, Dmards, Dose reduction, Etanercept, Gold nephropathy, Gold therapy, Gold toxicity, Guideline, Initial dose, Injectable gold, International kidney biopsy registry, Methotrexate, Natural course, Nephropathy, Nephrotic, Nephrotic syndrome, Nephrotoxicity, Nonsteroidal drugs, Nsaid, Older patients, Parenteral, Parenteral gold, Penicillamine, Penicillamine nephropathy, Penicillamine treatment, Placebo, Proteinuria, Randomized, Renal, Renal damage, Renal dysfunction, Renal effects, Renal function, Renal toxicity, Rheum, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthritis patients, Rheumatol, Schiff, Second biopsy, Serum creatinine, Serum creatinine concentration, Serum creatinine levels, Side effects, Sulfasalazine, Toxicity, Whelton.
Abstract
Abstract: Objective: To provide a review of the renal toxicity of disease-modifying antirheumatic drugs (DMARDs) currently used for the treatment of rheumatoid arthritis. Methods: Papers in American and European medical journals related to renal toxicity of DMARDs used for the treatment of rheumatoid arthritis were reviewed. Specific DMARDs reviewed were cyclosporine, gold, D-penicillamine, methotrexate, azathioprine, antimalarials, sulfasalazine, leflunomide, etanercept, infliximab, and DMARD combination therapy. Results: The renal toxicity of DMARDs varies widely. Cyclosporine, gold, and D-penicillamine all have a serious potential for renal side effects, particularly in the elderly or in patients with compromised renal function. Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) increases the potential for renal damage. In contrast, methotrexate, azathioprine, antimalarials, sulfasalazine, leflunomide, etanercept, and infliximab have relatively little renal toxicity. Conclusions: The potential for renal toxicity should always be considered when determining which DMARD to use for RA therapy. DMARDs that combine efficacy with negligible renal adverse effects should be used for the treatment of patients susceptible to DMARD-associated renal damage. Semin Arthritis Rheum 30:196-208. Copyright © 2000 by W.B. Saunders Company
Url:
DOI: 10.1053/sarh.2000.16641
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000278
- to stream Istex, to step Curation: 000278
- to stream Istex, to step Checkpoint: 001314
- to stream Main, to step Merge: 002525
- to stream Main, to step Curation: 002497
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis</title><author><name sortKey="Schiff, Michael H" sort="Schiff, Michael H" uniqKey="Schiff M" first="Michael H." last="Schiff">Michael H. Schiff</name></author><author><name sortKey="Whelton, Andrew" sort="Whelton, Andrew" uniqKey="Whelton A" first="Andrew" last="Whelton">Andrew Whelton</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9A2A4B563325534326DAF98B6AD439F5EF6F0F97</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1053/sarh.2000.16641</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-X5D9662V-C/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000278</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000278</idno><idno type="wicri:Area/Istex/Curation">000278</idno><idno type="wicri:Area/Istex/Checkpoint">001314</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001314</idno><idno type="wicri:doubleKey">0049-0172:2000:Schiff M:renal:toxicity:associated</idno><idno type="wicri:Area/Main/Merge">002525</idno><idno type="wicri:Area/Main/Curation">002497</idno><idno type="wicri:Area/Main/Exploration">002497</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis</title><author><name sortKey="Schiff, Michael H" sort="Schiff, Michael H" uniqKey="Schiff M" first="Michael H." last="Schiff">Michael H. Schiff</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>University of Colorado School of Medicine, Denver, CO; and Johns Hopkins University School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Whelton, Andrew" sort="Whelton, Andrew" uniqKey="Whelton A" first="Andrew" last="Whelton">Andrew Whelton</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>University of Colorado School of Medicine, Denver, CO; and Johns Hopkins University School of Medicine, Baltimore</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Seminars in Arthritis and Rheumatism</title><title level="j" type="abbrev">YSARH</title><idno type="ISSN">0049-0172</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000">2000</date><biblScope unit="volume">30</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="196">196</biblScope><biblScope unit="page" to="208">208</biblScope></imprint><idno type="ISSN">0049-0172</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0049-0172</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>DMARDs</term><term>Drug-drug interactions</term><term>renal toxicity</term><term>rheumatoid arthritis</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Abnormality</term><term>Adverse events</term><term>Adverse reactions</term><term>Antimalarial</term><term>Antirheumatic drugs</term><term>Arthritis</term><term>Arthritis rheum</term><term>Autoimmune diseases</term><term>Azathioprine</term><term>Biopsy</term><term>Consensus guidelines</term><term>Creatinine</term><term>Creatinine clearance</term><term>Cyclosporin</term><term>Cyclosporine</term><term>Dmard</term><term>Dmards</term><term>Dose reduction</term><term>Etanercept</term><term>Gold nephropathy</term><term>Gold therapy</term><term>Gold toxicity</term><term>Guideline</term><term>Initial dose</term><term>Injectable gold</term><term>International kidney biopsy registry</term><term>Methotrexate</term><term>Natural course</term><term>Nephropathy</term><term>Nephrotic</term><term>Nephrotic syndrome</term><term>Nephrotoxicity</term><term>Nonsteroidal drugs</term><term>Nsaid</term><term>Older patients</term><term>Parenteral</term><term>Parenteral gold</term><term>Penicillamine</term><term>Penicillamine nephropathy</term><term>Penicillamine treatment</term><term>Placebo</term><term>Proteinuria</term><term>Randomized</term><term>Renal</term><term>Renal damage</term><term>Renal dysfunction</term><term>Renal effects</term><term>Renal function</term><term>Renal toxicity</term><term>Rheum</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid arthritis patients</term><term>Rheumatol</term><term>Schiff</term><term>Second biopsy</term><term>Serum creatinine</term><term>Serum creatinine concentration</term><term>Serum creatinine levels</term><term>Side effects</term><term>Sulfasalazine</term><term>Toxicity</term><term>Whelton</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Objective: To provide a review of the renal toxicity of disease-modifying antirheumatic drugs (DMARDs) currently used for the treatment of rheumatoid arthritis. Methods: Papers in American and European medical journals related to renal toxicity of DMARDs used for the treatment of rheumatoid arthritis were reviewed. Specific DMARDs reviewed were cyclosporine, gold, D-penicillamine, methotrexate, azathioprine, antimalarials, sulfasalazine, leflunomide, etanercept, infliximab, and DMARD combination therapy. Results: The renal toxicity of DMARDs varies widely. Cyclosporine, gold, and D-penicillamine all have a serious potential for renal side effects, particularly in the elderly or in patients with compromised renal function. Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) increases the potential for renal damage. In contrast, methotrexate, azathioprine, antimalarials, sulfasalazine, leflunomide, etanercept, and infliximab have relatively little renal toxicity. Conclusions: The potential for renal toxicity should always be considered when determining which DMARD to use for RA therapy. DMARDs that combine efficacy with negligible renal adverse effects should be used for the treatment of patients susceptible to DMARD-associated renal damage. Semin Arthritis Rheum 30:196-208. Copyright © 2000 by W.B. Saunders Company</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Schiff, Michael H" sort="Schiff, Michael H" uniqKey="Schiff M" first="Michael H." last="Schiff">Michael H. Schiff</name></region><name sortKey="Whelton, Andrew" sort="Whelton, Andrew" uniqKey="Whelton A" first="Andrew" last="Whelton">Andrew Whelton</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002497 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002497 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:9A2A4B563325534326DAF98B6AD439F5EF6F0F97
|texte= Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis
}}
| This area was generated with Dilib version V0.6.33. |  |